Successful HIV treatment: Lessons learned

Journal of Managed Care Pharmacy

Volumn 12, Issue 7 SUPPL. B, 2006, Pages

  Cohen, Calvin J ^a,b,c,d  

^a Boston Community Research Initiative of New England   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

Acquired immunodeficiency syndrome (AIDS); Antiretroviral drugs; Highly active antiretroviral therapy (HAART); HIV resistance; Human immunodeficiency virus (HIV); Protease inhibitor

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CONFERENCE PAPER; CROSS RESISTANCE; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; HEALTH CARE COST; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; HEALTH CARE COSTS; HIV SEROPOSITIVITY; HUMANS; TREATMENT OUTCOME;

EID: 34548545291     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.s7-b.s6     Document Type: Conference Paper

References (17)

1. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280:35-41.
2. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-53.
3. Boehringer Ingelheim Pharmaceuticals. Data on file. 1996.
4. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996;10:975-81.
5. Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL. Abstract 448.
6. Cahn P, Hicks C, for the RESIST study teams. RESIST-1 (R-1) and RESIST-2 (R-2) 48-week meta-analyses demonstrate superiority of protease inhibitor (PI) tipranavir + ritonavir (TPV/r) over an optimized comparator PI (CPI/r) regimen in antiretroviral (ARV) experienced patients. Poster presented at: European AIDS Clinical Society 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland. Abstract LBPS3/8.
7. U.S. Food and Drug Administration. Tipranavir hearing. June 2005. Available at: www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4139b1-01-fda.htm. Accessed July 17, 2006.
8. Hornberger J, Kilby JM, Wintfeld N, Green J. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Res Hum Retroviruses. 2006;22:240-47.
9. Gulick R, Ribaudo H, Shikuma C, et al. ACTG 5095: zidovudine/lamivudine/ abacavir vs. zidovudine/lamivudine + efavirenz vs. zidovudine/lamivudine/ abacavir + efavirenz for initial HIV therapy. Paper presented at: 45th Interscience Conference of Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. Abstract H-416a.
10. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60.
11. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
12. Enejosa J, Zhong L, Cheng AK, for the 903E study team. Tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral naive HIV-infected patients: a 4-year follow-up. Poster presented at: European AIDS Clinical Society 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland. Abstract PE7.3/13.
13. Murphy R, da Silva B, McMillan F, et al. Seven-year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naïve subjects. Poster presented at: European AIDS Clinical Society 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland. Abstract PE7.9/3.
14. da Silva B, Albrecht M, Benson C, et al. Improved metabolic profile with replacement of stavudine by tenofovir DF after 6 years of a lopinavir/ ritonavirbased regimen. Paper presented at: 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; November 13-16, 2005; Dublin, Ireland. Abstract 62.
15. Mannheimer S, Morse E, Matts J. Sustained benefit from a long-term anti-retroviral (AR) adherence intervention: results of a large randomized clinical trial. Paper presented at: 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract LbOrB15.
16. Rode R, Vrijens B, Niemi K, Wikstrom K, Heuser R, Podsadecki T. Differences in treatment compliance between lopinavir/ritonavir (LPV/r) given once (QD) versus twice (BID) daily do not affect virologic or immunologic outcomes. Paper presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. Abstract H-522.
17. Gallant JE, DeJesus E, Arribas JR, et al., for the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60.